On July 1, 2024, marking the 103rd anniversary of the founding of the Communist Party of China, Raytec Biotech has achieved new breakthroughs in its solutions for ocular surface regeneration and repair. The company's independently developed Class III implantable medical device product, "Wet-state Bio-amnion," officially obtained the medical device registration certificate in Sichuan.
The first wet-state bio-amnion product to be launched in Sichuan
This product can be used for temporary coverage of superficial corneal defects and has significant therapeutic effects in post-operative repair of corneal ulcer, pterygium, viral keratitis, eye burns, and other conditions. It is the first wet bio-amnion product approved by the National Medical Products Administration to be launched in Sichuan, and also an important step for Raytec Biology to expand its business in Chengdu and cover the southwestern region. From now on, Raytec Biology has officially entered the era of "dual-engine" driven development with Guangzhou and Chengdu as its core hubs.
The only commercial amniotic membrane recommended in the "Expert Consensus on the Application of Amniotic Membrane in the Treatment of Corneal and Ocular Surface Diseases in China (2023)"
AMNIOCARE® cryopreservation technology, with a shelf life of up to 3 years
Strong biological activity, consistent biological structure with fresh amniotic membrane
Excellent repair effect for ocular surface injuries, equivalent to fresh amniotic membrane
Good flexibility, better adherence to wounds, similar to fresh amniotic membrane
As the first producer of wet-state bio-amnion approved by the National Medical Products Administration, Raytec Biology possesses natural competitive advantages in the field of bio-amnion with over 30 patented technologies including its unique quick cutting process technology and AMNIOCARE® frozen wet-state preservation technology.
Based on the group's existing technology foundation and the 50-mu industrialization base in Wenjiang, Chengdu, we will continue to explore and innovate, develop more and better regenerative and repair products, benefit a wide range of patients, and contribute to the high-quality development of the national medical and health sector.
